Drugs / IPM514
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06690476 | Oct 2024 → Jul 2026 overdue | esophageal squamous cell carcinoma | Peking University | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07203898 | Jun → Dec 2026 expected | esophageal squamous cell carcinoma | Beijing Immupeutics Medicine Technology Limited | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPM514 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07203898 ↗ |
| Modality | Vaccine | “2 cycles of vaccination” NCT06690476 ↗ |
| Route | Intramuscular | “Drug：IPM514 Intramuscular Injection” NCT06690476 ↗ |